Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: " Late presentation of sorafenib-associated rash: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Late presentation of sorafenib-associated rash: a case report | Sarkodie and Ross Journal of Medical Case Reports 2010 4 338 http www.jmedicalcasereports.eom content 4 1 338 jAc JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Late presentation of sorafenib-associated rash a case report Thomas Sarkodie Paul Ross Abstract Introduction Sorafenib an oral multitargeted tyrosine kinase inhibitor is licensed for the treatment of hepatocellular carcinoma. Rash is one of the most common side effects of its use generally appearing within days to a few weeks of commencing treatment. We report the first case of rash appearing nine months after starting treatment with sorafenib. Case presentation A 75-year-old Caucasian man initially presented with asymptomatic transient jaundice. He was diagnosed with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma after extensive investigation. He tolerated sorafenib 400 mg twice a day before presenting nine months later with a rash confirmed to be drug-induced. Conclusions Sorafenib is a drug of choice in Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. It can cause protracted rash quite late into treatment. Successful management of the rash could contribute to achieving stable disease in hepatocellular carcinoma over a significant period of time. Introduction Hepatocellular carcinoma HCC is the fifth most common neoplasm in the world and the third most frequent cause of cancer death worldwide 1 . The incidence of HCC is 500 000 to one million cases per year. HCC is closely associated with hepatic cirrhosis in the western world being found in about 70 of all cases. Treatment of HCC is effective in improving survival only when diagnosed at an early stage of the disease. Tumor staging at diagnosis is essential in deciding appropriate treatment. The most recognized staging systems for HCC currently include the i Okuda staging system ii Cancer of the Liver Italian Program CLIP scoring system and the iii Barcelona Clinic Liver Cancer BCLC staging Tables 1 and 2 2 . .